Stem cells-a hard sell to investors

A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2005-07, Vol.23 (7), p.798-800
Main Author: Giebel, Lutz B
Format: Article
Language:English
Subjects:
Agriculture
Bioinformatics
Biomedical Engineering/Biotechnology
Biomedicine
Biopsy
Biotechnology
Biotechnology - economics
Biotechnology industry
Bone marrow
Cartilage
commentary
Ethics
Humans
Intellectual property
Investments
Life Sciences
Market potential
Neurodegenerative Diseases - therapy
Product development
Stem cell transplantation
Stem Cell Transplantation - economics
Stem Cell Transplantation - ethics
Stem Cell Transplantation - legislation & jurisprudence
Stem Cells
Venture capital
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0705-798